Loading clinical trials...
Loading clinical trials...
This randomized pilot study will be conducted in men with metastatic castration resistant prostate cancer (mCRPC) within 3 months of initiating abiraterone or enzalutamide. The purpose of this pilot s...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
NCT07285694 · Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT06894511 · Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT03724747 · Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT04516161 · Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT04052204 · Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions